Ozempic: What Do People Take Ozempic For in Modern Health?

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Ozempic, was first approved in 2017 for blood sugar management in type 2 diabetes patients. Over the past five years, clinical research has revealed that semaglutide produces sustained weight loss in individuals with obesity, regardless of diabetes status, making it relevant to millions of Americans seeking effective metabolic support.

How Semaglutide Works for Weight Management

Semaglutide mimics a hormone called glucagon-like peptide-1 (GLP-1), which tells your brain when you feel full and hungry. By activating GLP-1 receptors in the hypothalamus and elsewhere in your body, semaglutide slows how quickly your stomach empties food into your intestines, increases feelings of satiety, and reduces cravings for high-calorie foods. This mechanism addresses appetite regulation at the biological level, rather than relying on willpower alone.

The medication also improves how your body handles blood sugar by stimulating insulin release when glucose levels rise. This dual action on appetite and metabolism explains why semaglutide produces weight reductions averaging 15–22% of body weight in clinical trials. Studies published in the New England Journal of Medicine and Diabetes Care demonstrate consistent results across diverse patient populations.

Original Medical Uses Beyond Weight Loss

Semaglutide's primary FDA indication remains type 2 diabetes management, where it reduces hemoglobin A1C levels by 1.5–2.0 percentage points and lowers cardiovascular death risk in patients with established heart disease. For individuals with diabetes who are overweight or obese, the weight loss benefit adds protective value against progression of kidney disease and hypertension. Many endocrinologists prescribe semaglutide as a first-line agent because it addresses both blood sugar and body weight simultaneously.

Recent evidence suggests semaglutide may offer cardiovascular protection beyond diabetes control. The SUSTAIN-6 and SELECT trials found that semaglutide reduces major adverse cardiovascular events in people with established heart disease or high cardiovascular risk, even among those without diabetes, though this use remains primarily research-focused outside specialized cardiology settings.

Weight Loss Applications and Growing Popularity

The rise of semaglutide for weight management has created substantial demand among adults with obesity seeking sustainable metabolic change. Patients report reduced food preoccupation, decreased hunger between meals, and ability to maintain lower calorie intake without the constant psychological struggle typical of diet-only approaches. This psychological benefit explains why semaglutide adherence rates exceed 70% in real-world studies, compared to 30–40% for traditional diet programs.

Healthcare providers increasingly recognize that obesity itself is a chronic medical condition requiring pharmacologic support, not a personal failing. Semaglutide offers patients a tool that works with their biology rather than against their appetite-regulating hormones. PlexusDx delivers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, with no insurance requirement and HSA/FSA eligibility, making personalized GLP-1 therapy accessible to diverse patient populations.

Genetic Personalization and Precision GLP-1 Therapy

Not all patients respond identically to semaglutide because genetic variation in GLP-1 receptor structure, FTO (fat mass regulator), MC4R (melanocortin-4 receptor), and GIPR (glucose-dependent insulinotropic polypeptide receptor) influences how their bodies metabolize appetite signals. PlexusDx Precision Peptide Genetic Test maps 14 distinct metabolic pathways involving 49 peptides to identify which genetic variants affect your individual response to GLP-1 therapy. This enables your provider to match you with the most effective compound and protocol for your genetic makeup.

Patients with certain GIPR rs1800437 or GLP1R rs6923761 variants may achieve superior results with semaglutide, while others benefit from combination therapy like GLP-Squared (semaglutide plus tirzepatide). The Precision Peptide test costs $298, providing data-driven guidance that removes guesswork from personalized medicine. This approach represents a shift from one-size-fits-all prescribing toward truly precision health.

Compounded Semaglutide: Access, Cost, and Quality Standards

PlexusDx sources all semaglutide medications from licensed 503A compounding pharmacies, which follow identical quality, sterility, and potency standards as pharmaceutical manufacturers. Unlike 503B pharmacies that produce bulk compounds, 503A facilities compound medications for individual patients in small batches under direct pharmacist supervision. This distinction ensures each dose meets USP standards and undergoes rigorous quality control before shipment to your home.

Compounded semaglutide injections begin at $189/mo (or $149/mo on the 6-month plan) across PlexusDx's three commitment tiers, with no membership fees, insurance requirements, or flat per-compound pricing increases. Your dose may need to go up as your body adjusts, but your monthly price remains stable. PlexusDx serves all 50 states with rapid shipping and provides access to board-certified physicians who manage your treatment protocol directly, eliminating delays typical of traditional insurance-dependent care models.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can I use semaglutide for weight loss if I don't have diabetes?

Yes. Semaglutide reduces appetite and body weight through GLP-1 receptor activation regardless of diabetes status. Clinical trials demonstrate that adults with obesity who do not have diabetes achieve 15–22% weight loss with semaglutide therapy. PlexusDx evaluates each patient individually and prescribes compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan for eligible candidates seeking sustainable weight management.

How much weight do most people lose on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Does PlexusDx require insurance or a membership fee?

No. PlexusDx serves all 50 states with no insurance requirement and no membership fees. Compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan and are HSA/FSA eligible. You pay a flat monthly rate regardless of your dose level—your dose may go up, but your price won't.

What are the common side effects of semaglutide?

Most common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation in the first 4–8 weeks. These typically resolve as your body adjusts. Serious but rare risks include acute pancreatitis and gallbladder complications. Your PlexusDx physician monitors you throughout treatment and adjusts your protocol if side effects become problematic.

How does PlexusDx Precision Peptide Genetic Testing help choose the right GLP-1 medication?

The test analyzes 150+ genetic insights across 14 metabolic pathways to identify your variants in GIPR and FTO, and MC4R receptors. These variants influence how strongly you respond to semaglutide versus tirzepatide or combination therapy. At $298, the test enables your provider to optimize your prescription based on your unique genetic predispositions rather than trial-and-error.

Related Reading

• Lifemd Ozempic
• Form Health Weight Loss
• Form Health Zepbound
• Eden Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.